EGEN-2784

Asset

Gene-edited porcine kidney with glycan xenoantigen deletions, PERV inactivation, and seven human transgenes for xenotransplantation.

Stage
Phase 1
Modality
Cell therapy
Target
Not known
1
Indication
0
Trials
1
Developer

Indications

1
  • End-stage kidney disease

    Phase 1, doi.org, 3 Sept 2026

In the full profile

  • Owner and partners1
  • Evidence for its targets1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets